Monday, 26 June 2017

Generics News

  • US firms lobbying to protect patents in India: Report

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 24 Oct, 2013

    Singapore: An Indian news report that appeared in Business Line quoted an unidentified DIPP official who claimed that top officials of many US pharmaceutical companies recently met the Depa...Read more

  • Merck aims to expand its China business

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 05 Aug, 2014

    Singapore: Leading pharma giant Merck has reinforced its commitments towards China, in a bid to strengthen its position among emerging markets. Merck aims to construct its pioneering new ph...Read more

  • Blogger sued by pharma firm for the first time in India

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 10 Sep, 2012

    Mumbai: NATCO Pharma has filed a lawsuit against Mr Shamnaad Basheer, professor, West Bengal National University of Juridical Sciences, Kolkata, over his alleged defamatory remarks publishe...Read more

  • Actavis sets up APAC headquarter in Singapore

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 04 Apr, 2014

    Singapore: Global generics firm, Actavis, has opened its regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region. In addit...Read more

  • Indian regulator cracks down on banned drugs

    Generics |  News | By Narayanan Suresh | 0 Comment | 21 Jan, 2013

    Bangalore: As a first step to prevent misuse of drugs, which have been banned abroad from being sold freely in the country, Drug Controller General of India (DGCI) has directed all companie...Read more

  • Why Mylan sued US FDA over Diovan generic?

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 04 Oct, 2012

    Multinational pharmaceutical company Mylan sued the US Food and Drug Administration (FDA) for approval to sell a generic version of Novartis' blockbuster anti-hypertensive drug Diovan (vals...Read more

  • Ranbaxy now recalls 64,000 bottles of generic heart drug

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 11 Mar, 2014

    Singapore: Ranbaxy Laboratories, which is already reeling under several regulatory rebukes owing to quality apprehensions, recalled more than 64,000 bottles containing tablets of atorvastat...Read more

  • APAC Epilepsy Therapeutics market to touch $1.5 bn by 2019

    Generics |  Analysis | By BioSpectrum Bureau | 0 Comment | 28 Feb, 2014

    Singapore: The epilepsy therapeutics market value in the Asia-Pacific (APAC) region, Australia, China, India and Japan, is expected to increase moderately, climbing from USD1.1 billion in 2...Read more

  • Pfizer, Mylan settle litigation over Detrol LA generic

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 10 Sep, 2012

    Singapore: Pfizer has settled its litigation against Mylan and Mylan Pharmaceuticals relating to Pfizer's patents covering Detrol LA (tolterodine tartrate) extended-release capsules. The p...Read more

  • Mundipharma, Horizon subsidiary sign arthritis deal

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 13 Nov, 2013

    Singapore: Mundipharma has signed an exclusive agreement with the Swiss subsidiary of Horizon Pharma for the commercialization and distribution of Lodotra in the Middle East and African reg...Read more

  • Aurobindo diabetes generic gets US FDA nod

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 04 Feb, 2014

    Singapore: Aurobindo Pharma has received US FDA approval for Repaglinide tablets, the generic equivalent of Novo Nordisk's Prandin Tablets. The drug is indicated as an adjunct to diet and...Read more

  • Patents worth $60 billion set to expire by 2019

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 07 Mar, 2012

    The year 2012 has brought a world of opportunities for Indian biotech companies, with big-wig biotech firms in the West facing a spree of patent expiration of their blockbuster products. Gr...Read more

  • Cipla nurtures global vision for affordable drugs

    Generics |  Analysis | By BioSpectrum Bureau | 0 Comment | 13 Jun, 2012

    The king of generics, Cipla, has been aggressive in expanding product portfolio and reaching out to international market. Without missing any opportunity to serve the healthcare industry in...Read more

  • Gilead allows sublicense of HIV drug to generic firms

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 25 Jul, 2014

    Singapore: HIV drug developer, Gilead Sciences has partnered with Medicines Patent Pool (MPP) to expand access to Gilead's investigational drug tenofovir alafenamide (TAF) for HIV and hepat...Read more

  • Bayer plea for stay on compulsory license dismissed

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 17 Sep, 2012

    Bangalore: The Intellectual Property Appellate Board in Chennai, India, has rejected pharma major Bayer's petition seeking a stay on compulsory license to Hyderabad-based Natco Pharma for s...Read more

  • Perrigo rejects Mylan's acquisition bid

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 28 Apr, 2015

    Singapore: Irish firm, Perrigo, has declined the acquisition offer from Mylan revalued at USD60 per share in cash and 2.2 Mylan ordinary shares for each ordinary Perrigo share. The Board p...Read more

  • Ranbaxy, Lundbeck face EU fury for blocking generics

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 04 Jun, 2013

    Singapore: The European Commission (EC) is going to fine seven generic drug firms, including India-based Ranbaxy and Denmark-based Lundbeck, for limiting the supply of cheaper medicines to ...Read more

  • FDA flags GMP issues at Impax's Taiwan facility

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 31 Jul, 2014

    Singapore: Regulatory hurdles continue to haunt Impax Laboratories and its experimental drug, Rytary, that treats idiopathic Parkinson's disease. After facing a tough time with the FDA at t...Read more

Survey Box

Will Asia- Pacific healthcare IT market hit the double digit growth in the next five years?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls